ArriVent BioPharma, Inc. AVBP
Set alert
13.84 USD +0.49 +3.67%
As of Nov 3, 11:05 AM ET
13.47 Day range 13.94
11.36 52-week range 35.83
- YTD
- -31.21%
- 1 year
- -21.36%
- Open
- 13.47
- Prev close
- 13.35
- Mkt cap
- 681.43M
- Vol
- 200.00K
- Avg vol
- 1.21M
- EPS
- -3.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.47
- High
- 13.94
- Forward P/E
- -5.64
- Beta
- 1.35
- Short ratio
- 13.52
- Inst. own
- 100.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 26.34
- 200-d avg
- 27.09
- 1y target
- 22.30
MAX chart
Events in this range
- Aug 11, 2025Earnings: -0.9; estimate -0.7; surprise -28.57%
- Nov 10, 2025Earnings: -0.83; estimate -0.78; surprise -6.41%
- Mar 5, 2026Earnings: -0.78; estimate -0.87; surprise 10.34%
- May 11, 2026Earnings: -0.96; estimate -0.88; surprise -9.09%
- Aug 12, 2026Earnings: -1.05; estimate -0.98732; surprise -6.35%
- Oct 7, 2026Rating: Truist Securities · Buy → Buy
- Oct 7, 2026Rating: Jones Trading · Buy → Buy
- Oct 7, 2026Rating: Citigroup · Buy → Buy
- Oct 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 16, 2026Rating: BTIG · Buy → Buy
- Oct 20, 2026Rating: B. Riley Securities · Buy → Buy
Signals (59)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 16, 2026 | 7 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
Newest 20 of 59.
Financial health
Altman Z-Score
12.15 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 2
Valuation
P/E -4.7×
FY 2021 5y median -9.2× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 2.5×
FY 2021 5y median 3.3× FY 2025
P/FCF -4.8×
FY 2021 5y median -11.4× FY 2025
EV/EBITDA -4.4×
FY 2021 5y median -4.4× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -20.8%
FY 2021 5y median -8.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -54.1%
FY 2021 5y median -45.8% FY 2025
ROIC -57.8%
FY 2021 5y median -36.6% FY 2025
ROA -49.9%
FY 2021 5y median -42.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -88.2%
FY 2021 FY 2025
EPS (diluted) -68.8%
FY 2021 FY 2025
Free Cash Flow -128.7%
FY 2021 FY 2025
Financial Health
Current Ratio 12.8×
FY 2021 5y median 13.8× FY 2025
Quick Ratio 12.8×
FY 2021 5y median 13.8× FY 2025
Debt / Equity 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2021 5y median 0.7× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31